Accepting new patients
Joseph G. Crompton, MD, PhD
- Surgical Oncology
Surgical Oncology
|
200 Medical Plaza, Suite B265, Los Angeles, CA 90095
US
About
Dr. Joseph G. Crompton is a surgeon-scientist with a primary clinical focus on the multi-modality treatment of melanoma and soft tissue sarcoma. His current research interests include characterizing the immune response to cancer and developing novel immunotherapies to treat advanced disease.
Languages
Education
Medical Board Certification
Surgery, American Board of Surgery, 2019
Fellowships
Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 2020
Surgical Oncology, National Cancer Institute, 2015
Residency
General Surgery, UCLA School of Medicine, 2018
Degrees
PhD, Magdalene College University of Cambridge, 2016
MD, Johns Hopkins University School of Medicine, 2009
Recognitions
- Wilma Miley Morton Award for Excellence in Research, David Geffen School of Medicine, 2018
- Excellence in Teaching with Humanism Residents Award, David Geffen School of Medicine, 2017
- Scientific Day Resident Award, UCLA Department of Surgery, Longmire Surgical Society, 2016
- See More
Locations
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Medical Services
Areas of Focus
Research
Publications
- Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP. Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cell Mol Immunol. 2015.
- Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Research 2015.
- Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight. 2017.
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- L.A. Care
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Recognitions
- Wilma Miley Morton Award for Excellence in Research, David Geffen School of Medicine, 2018
- Excellence in Teaching with Humanism Residents Award, David Geffen School of Medicine, 2017
- Scientific Day Resident Award, UCLA Department of Surgery, Longmire Surgical Society, 2016
- American College of Surgeons Leadership and Advocacy Summit Resident Award, 2016
- Clinical Cancer Research Federal Technology Transfer Award, National Cancer Institute, 2014
- Wellcome Trust Translational Medicine and Therapeutics Research Fellowship, 2012